FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation.